# A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

> **NCT05723198** · PHASE3 · RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 595 (estimated)

## Conditions studied

- Areata Alopecia
- Alopecia
- Hypotrichosis
- Hair Diseases
- Skin Diseases
- Pathological Conditions, Anatomical

## Interventions

- **DRUG:** Baricitinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05723198
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-27
- **Primary completion:** 2028-03
- **Final completion:** 2030-02
- **Target enrollment:** 595 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05723198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05723198, "A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05723198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*